Lee YT, et al. - Authors undertook this work to assess the clinical and microbiological characteristics of breakthrough Acinetobacter bacteremia during carbapenem therapy and to assess the efficacy of various antimicrobial therapies. A high mortality rate was observed among patients with breakthrough Acinetobacter bacteremia during carbapenem therapy. They suggested practicing caution while using tigecycline for the treatment of breakthrough Acinetobacter bacteremia that develops during carbapenem therapy.